Valuations make buyers out of biotechs once seen as takeover targets

05/10/2013 | Reuters

Rising stock valuations due to promising drug data have transformed biotech drugmakers from acquisition targets into potential buyers, analysts said. Aside from rich valuations, easy access to financing and low interest rates provided alternatives to funding research and commercialization, a health banker said.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA